La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Mayne Pharma Group Crescita futura

Future criteri di controllo 1/6

Si prevede che Mayne Pharma Group aumenterà gli utili e i ricavi rispettivamente del 99.8% e 15.6% all'anno, mentre si prevede che l'EPS crescerà del 99.9% all'anno.

Informazioni chiave

131.3%

Tasso di crescita degli utili

131.6%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	31.7%
Tasso di crescita dei ricavi	10.9%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	17 May 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 06

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 01

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Nov 16

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Nov 10

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

May 17

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

Mar 22

How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

Mar 01

What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Feb 08

Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Jan 18

Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Dec 27

Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

Dec 09

A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

Nov 24

Previsioni di crescita degli utili e dei ricavi

ASX:MYX - Stime future degli analisti e dati finanziari passati (AUD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2026	486	-2	N/A	N/A	1
6/30/2025	426	-20	N/A	38	2
6/30/2024	388	-169	-36	-15	N/A
3/31/2024	354	-221	-35	-15	N/A
12/31/2023	319	-274	-34	-15	N/A
9/30/2023	251	-296	-148	-29	N/A
6/30/2023	184	-317	-262	-43	N/A
3/31/2023	97	-280	-275	-54	N/A
12/31/2022	59	-257	-287	-64	N/A
9/30/2022	108	-233	-153	-36	N/A
6/30/2022	157	-209	-19	-7	N/A
3/31/2022	250	-151	-13	3	N/A
12/31/2021	342	-93	-7	13	N/A
9/30/2021	372	-151	14	36	N/A
6/30/2021	401	-208	34	59	N/A
3/31/2021	420	-232	56	82	N/A
12/31/2020	439	-256	78	106	N/A
9/30/2020	448	-174	72	109	N/A
6/30/2020	457	-93	65	113	N/A
3/31/2020	467	-196	61	109	N/A
12/31/2019	478	-300	56	106	N/A
9/30/2019	502	-290	40	106	N/A
6/30/2019	525	-279	25	107	N/A
3/31/2019	543	-118	28	117	N/A
12/31/2018	561	43	31	127	N/A
9/30/2018	546	-46	29	124	N/A
6/30/2018	530	-134	27	121	N/A
3/31/2018	526	-146	N/A	111	N/A
12/31/2017	521	-158	N/A	100	N/A
9/30/2017	547	-35	N/A	42	N/A
6/30/2017	573	89	N/A	-15	N/A
3/31/2017	504	90	N/A	-30	N/A
12/31/2016	435	91	N/A	-44	N/A
9/30/2016	351	64	N/A	5	N/A
6/30/2016	267	37	N/A	54	N/A
3/31/2016	238	30	N/A	49	N/A
12/31/2015	209	23	N/A	44	N/A
9/30/2015	175	15	N/A	33	N/A
6/30/2015	141	8	N/A	22	N/A
3/31/2015	137	12	N/A	21	N/A
12/31/2014	133	17	N/A	20	N/A
9/30/2014	138	19	N/A	23	N/A
6/30/2014	143	21	N/A	26	N/A
3/31/2014	135	15	N/A	24	N/A
12/31/2013	126	8	N/A	21	N/A
9/30/2013	105	3	N/A	14	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che MYX rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che MYX rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che MYX rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di MYX ( 15.6% all'anno) crescerà più rapidamente del mercato Australian ( 5.3% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di MYX ( 15.6% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di MYX è previsto essere elevato tra 3 anni

Mayne Pharma Group Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

No longer forecast to breakeven

Consensus revenue estimates increase by 14%, EPS downgraded

Forecast to breakeven in 2026

Consensus estimates of losses per share improve by 13%

Consensus estimates of losses per share improve by 13%

Consensus revenue estimates fall by 19%

Recent updates

New major risk - Financial position

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

New minor risk - Profitability

Consensus revenue estimates increase by 14%, EPS downgraded

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Consensus estimates of losses per share improve by 13%

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Consensus estimates of losses per share improve by 13%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Consensus revenue estimates fall by 19%

Price target decreased by 24% to AU$3.86

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Consensus revenue estimates fall by 11%

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Consensus forecasts updated

Price target decreased to AU$0.37

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Price target decreased to AU$0.40

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

Price target increased to AU$0.43

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Price target decreased to AU$0.36

Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 97%

Mayne Pharma Expands U.S Dermatology Portfolio

Price target increased to AU$0.48

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Independent Non-Executive Director recently bought AU$137k worth of stock

Price target decreased to AU$0.42

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?